Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#2245 Metastatic VIPOMA, Co-Secreting Insulin, with Complete Response to Lanreotide Combined with Capecitabine and Temozolamide

Introduction: VIPomas are rare neuroendocrine tumors (NETs) associated with vasoactive intestinal polypeptide (VIP) hypersecretion causing watery diarrhea, hypokalaemia and achlorhydria. They originate mostly in the pancreas and 60-80% are malignant. Hormonal co-secretion is rarely reported.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Marques B

Authors: Marques B, Martins R, Ribeiro J, Couto J, Ferrão H,

Keywords: vipoma, neuroendocrine, lanreotide, capecitabine, temozolamide,

#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience

Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Antonuzzo A, Luca G, Vasile E,

Keywords: everolimus SSA,

#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)

Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hentic O, Cros J, Rebours V, Zappa M, Maire F,

Keywords: neuroendocrine tumor, treatment, temozolomide, MGMT,

#460 Treatment of Unresectable Metastatic GEP NETs: Data From a Prospective Observational Unicentric Study

Introduction: In 2010 Everolimus, Sunitinib and Capecitabine plus Temozolamide confirmed efficacy in NETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fonseca P, Galvan J, Gutierrez E, Álvarez C, Pérez Q,

Keywords: gep-net, SSA, Everolimus, Sunitinib, Temozolomide, Capecitabine,

#241 One-year Response to Everolimus in a Case of Advanced Pancreatic NET

Introduction: A stage IV pancreatic NET (30 mitoses/10 PF and Ki-67 index=40%) with liver and peritoneal metastases was diagnosed in a 35-year-old woman in June 2008. Characteristics: ECOG2 and CgA 1701 ng/ml.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: J Fonseca P, Vietez J, Galvan J, Crespo G, Astudillo A,

Keywords: pancreatic neuroendocrine tumor, Everolimus, Somatostatin Analogues, chemotherapy,